| 1 |
Ma M, Hou C, Liu J. Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation. Front Cardiovasc Med 2023;10. [DOI: 10.3389/fcvm.2023.1148486] [Reference Citation Analysis]
|
| 2 |
Zulkapli R, Muid SA, Wang SM, Nawawi H. PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells. IJMS 2023;24:5098. [DOI: 10.3390/ijms24065098] [Reference Citation Analysis]
|
| 3 |
Poznyak AV, Sukhorukov VN, Eremin II, Nadelyaeva II, Gutyrchik NA, Orekhov AN. Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis. Biomedicines 2023;11. [PMID: 36831039 DOI: 10.3390/biomedicines11020503] [Reference Citation Analysis]
|
| 4 |
Buso G, Faggin E, Rosenblatt-Velin N, Pellegrin M, Galliazzo S, Calanca L, Rattazzi M, Mazzolai L. The Role of Neutrophils in Lower Limb Peripheral Artery Disease: State of the Art and Future Perspectives. Int J Mol Sci 2023;24. [PMID: 36674682 DOI: 10.3390/ijms24021169] [Reference Citation Analysis]
|
| 5 |
Mensink FB, Los J, Ten Cate TJF, Oemrawsingh RM, Brouwer MA, El Messaoudi S, van Royen N, Cornel JH, Riksen NP, van Geuns RJM. Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. Front Cardiovasc Med 2022;9:1061346. [PMID: 36568547 DOI: 10.3389/fcvm.2022.1061346] [Reference Citation Analysis]
|
| 6 |
Raheem Lateef Al-awsi G, Hadi Lafta M, Hashim Kzar H, Samieva G, Alsaikhan F, Ahmad I, Mahmood Saleh M, Alamin Altoum A, Aravindhan S, Fakri Mustafa Y, Mahmoudi R, Mohammadi A. PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis. International Immunopharmacology 2022;113:109318. [DOI: 10.1016/j.intimp.2022.109318] [Reference Citation Analysis]
|
| 7 |
Salekeen R, Haider AN, Akhter F, Billah MM, Islam ME, Didarul Islam KM. Lipid oxidation in pathophysiology of atherosclerosis: Current understanding and therapeutic strategies. International Journal of Cardiology Cardiovascular Risk and Prevention 2022;14:200143. [DOI: 10.1016/j.ijcrp.2022.200143] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 8 |
Ou Z, Yu Z, Liang B, Zhao L, Li J, Pang X, Liu Q, Xu C, Dong S, Sun X, Li T. Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients. Front Cardiovasc Med 2022;9:939791. [PMID: 36017088 DOI: 10.3389/fcvm.2022.939791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Tirandi A, Montecucco F, Liberale L. Physical activity to reduce PCSK9 levels. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.988698] [Reference Citation Analysis]
|
| 10 |
Jaén RI, Povo-Retana A, Rosales-Mendoza C, Capillas-Herrero P, Sánchez-García S, Martín-Sanz P, Mojena M, Prieto P, Boscá L. Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release. Int J Mol Sci 2022;23:9114. [PMID: 36012389 DOI: 10.3390/ijms23169114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 11 |
Pereira M, Matuszewska K, Glogova A, Petrik J. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy. Cancers 2022;14:3500. [DOI: 10.3390/cancers14143500] [Reference Citation Analysis]
|
| 12 |
Ugovšek S, Šebeštjen M. Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall. JCM 2022;11:3625. [DOI: 10.3390/jcm11133625] [Reference Citation Analysis]
|
| 13 |
Ortona S, Barisione C, Ferrari PF, Palombo D, Pratesi G. PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery. JCM 2022;11:3638. [DOI: 10.3390/jcm11133638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Azar Y, Gannagé-Yared MH, Naous E, Ayoub C, Abou Khalil Y, Chahine E, Elbitar S, Ghaleb Y, Boileau C, Varret M, El Khoury P, Abifadel M. Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren. Metabolites 2022;12. [PMID: 35736437 DOI: 10.3390/metabo12060504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Bhansali S, Yadav AK, Bakshi C, Dhawan V. Interleukin-35 Mitigates ox-LDL-Induced Proatherogenic Effects via Modulating miRNAs Associated with Coronary Artery Disease (CAD). Cardiovasc Drugs Ther 2022. [PMID: 35435604 DOI: 10.1007/s10557-022-07335-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Scalise V, Lombardi S, Sanguinetti C, Nieri D, Pedrinelli R, Celi A, Neri T. A novel prothrombotic role of proprotein convertase subtilisin kexin 9: the generation of procoagulant extracellular vesicles by human mononuclear cells. Mol Biol Rep 2022. [PMID: 35412175 DOI: 10.1007/s11033-022-07433-x] [Reference Citation Analysis]
|
| 17 |
Puccini M, Landmesser U, Rauch U. Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis. Metabolites 2022;12:226. [DOI: 10.3390/metabo12030226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. J Am Heart Assoc 2022;11:e023328. [PMID: 35048716 DOI: 10.1161/JAHA.121.023328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Aghamajidi A, Gorgani M, Shahba F, Shafaghat Z, Mojtabavi N. The potential targets in immunotherapy of atherosclerosis. Int Rev Immunol 2021;:1-18. [PMID: 34779341 DOI: 10.1080/08830185.2021.1988591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Jin P, Gao D, Cong G, Yan R, Jia S. Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE-/- Mice. Front Cardiovasc Med 2021;8:746989. [PMID: 34660746 DOI: 10.3389/fcvm.2021.746989] [Reference Citation Analysis]
|
| 21 |
Martinez LO, Perret B, Genoux A. Update on proprotein convertase subtilisin/kexin type 9 inhibitors, lipoprotein(a) and cardiovascular risk. Curr Opin Lipidol 2021;32:324-7. [PMID: 34472540 DOI: 10.1097/MOL.0000000000000771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 22 |
Sundararaman SS, Döring Y, van der Vorst EPC. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines 2021;9:793. [PMID: 34356856 DOI: 10.3390/biomedicines9070793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
